Specific inhibition of the endothelin A receptor with ZD4054: Clinical and pre-clinical evidence

British Journal of Cancer

Volumn 92, Issue 12, 2005, Pages 2148-2152

  Morris, C D ^a   Rose, A ^a   Curwen, J ^a   Hughes, A M ^a   Wilson, D J ^a   Webb, D J ^b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cancer; Endothelin A receptor; Receptor specificity; Volunteer studies; ZD4054

Indexed keywords

ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; PLACEBO; UNCLASSIFIED DRUG; ZD 4054;

ADULT; ARTICLE; BLOOD LEVEL; BRACHIAL ARTERY; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INFUSION; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; FOREARM; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASOCONSTRICTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; ENDOTHELIN-1; HUMANS; RADIOLIGAND ASSAY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; VASOCONSTRICTION;

EID: 22044435149     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602676     Document Type: Article

References (26)

1. Bagnato A, Catt KJ (1998) Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol Metab 9: 378-383
2. Bagnato A, Spinella F (2003) Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 14: 44-50
3. Bagnato A, Tecce R, Di Castro V, Catt KJ (1997) Activation of mitogenic signaling by endothelin 1 in ovarian carcinoma cells. Cancer Res 57: 1306-1311
4. Battistini B, Chailler P, D'Orleans-Juste P, Briere N, Sirois P (1993) Growth regulatory properties of endothelins. Peptides 14: 385-399
5. Bradbury RH, Bath C, Butlin RJ, Dennis M, Heys C, Hunt SJ, James R, Mortlock AA, Summer NF, Tang EK, Telford B, Whiting E, Wilson C (1997) New non-peptide endothelin-A receptor antagonists: synthesis, biological properties, and structure - activity relationships of 5-(dimethylamino)-N-pyridyl-, -N-pyrimidinyl, -N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides. J Med Chem 40: 996-1004
6. Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, Donehower R, Leahy TL, Carr RA, Isaacson JD, Janus TJ, Andre A, Hosmane BS, Padley RJ (2002) Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 20: 2171-2180
7. 50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108
8. Curtis N, Anderson E, Brooks N, Curwen J (2005) ZD4054 blocks ET-1-stimulated phosphorylation of p44/42 mitogen-activated protein kinase and proliferation of osteoblast cells. Proc Am Assoc Cancer Res 46: 354 (abstract 1512)
9. Curtis N, Howard Z, Brooks N, Curwen J (2004) ZD4054 specifically inhibits endothelin A receptor-mediated anti-apoptotic effects, but not endothelin B receptor-mediated pro-apoptotic effects. Eur J Cancer Suppl 2: 27 (abstract 78)
10. Del Bufalo D, Di Castro V, Biroccio A, Varmi M, Salani D, Rosanò L, Trisciuoglio D, Spinella F, Bagnato A (2002) Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 61: 524-532
11. Dreicer R, Curtis N, Morris C, Wilson D, Hughes A, Le Maulf F, Howard Z, Brooks N, Curwen J (2005) ZD4054 specifically inhibits endothelin A receptor-mediated effects but not endothelin B receptor-mediated effects. Proc ASCO Multidisciplinary Prostate Cancer Sympos 153: 153 (abstract 237)
12. Kopetz ES, Nelson JB, Carducci MA (2002) Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest New Drugs 20: 173-182
13. Nelson JB (2003) Endothelin inhibition: novel therapy for prostate cancer. J Urol 170: S65-S68
14. Nelson J, Bagnato A, Battistini B, Nisen P (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3: 110-116
15. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW (1995) Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1: 944-949
16. Nelson JB, Nguyen SH, Wu-Wong JR, Opgenorth TJ, Dixon DB, Chung LW, Inoue N (1999) New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 53: 1063-1069
17. Okazawa M, Shiraki T, Ninomiya H, Kobayashi S, Masaki T (1998) Endothelin-induced apoptosis of A375 human melanoma cells. J Biol Chem 273: 12584-12592
18. Pirtskhalaishvili G, Nelson JB (2000) Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 44: 77-87
19. Rolinski B, Geier SA, Sadri I, Klauss V, Bogner JR, Ehrenreich H, Goebel FD (1994) Endothelin-1 immunoreactivity in plasma is elevated in HIV-1 infected patients with retinal microangiopathic syndrome. Clin Investig 72: 288-293
20. Rosanò L, Di Castro V, Spinella F, Natali PG, Bagnato A (2005) ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances cytotoxicity of paclitaxel in human ovarian carcinoma in vitro and in vivo. Proc Am Assoc Cancer Res 46: 1372 (abstract 5830)
21. Rosanò L, Varmi M, Salani D, Di Castro V, Spinella F, Natali PG, Bagnato A (2001) Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 61: 8340-8346
22. Spinella F, Rosano L, Di Castro V, Natali PG, Bagnato A (2002) Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem 277: 27850-27855
23. A receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol 134: 648-654
24. Strachan FE, Newby DE, Sciberras DG, McCrea JB, Goldberg MR, Webb DJ (2002) Repeatability of local forearm vasoconstriction to endothelin-1 measured by venous occlusion plethysmography. Br J Clin Pharmacol 54: 386-394
25. Strachan FE, Spratt JC, Wilkinson IB, Johnston NR, Gray GA, Webb DJ (1999) Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 33: 581-585
26. Wilkinson IB, Webb DJ (2001) Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol 52: 631-646